257280-25-4Relevant academic research and scientific papers
Method of preparing Quinoline-5,8-dione derivatives for TGase 2 inhibitor
-
Paragraph 0377-0380, (2020/04/28)
I Is -5,8- of the quinoline, dione derivative compound. of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound of Formula, TGase 2 has, inhibitory effects TGase 2, and thus the pharmaceutical composition may be useful for preventing or treating disorders or diseases mediated by TGase 2 or inhibiting. (by machine translation)
HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY
-
Paragraph 0111; 0144, (2020/06/19)
The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
BTK INHIBITOR COMPOUNDS
-
Page/Page column 30; 31, (2019/05/22)
The invention provides BTK Inhibitor compounds, pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
Reversible covalent Bruton's tyrosine kinase inhibitor, pharmaceutical composition and application thereof
-
Paragraph 0149-0151, (2019/12/02)
The invention discloses a reversible covalent Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition and application of the compound and the pharmaceutical composition in preparation of drugs for treating diseases, disorders or symptoms benefitting from inhibition of Bruton's tyrosine kinase activity. The compound provided by the invention has strong in-vitro BTK kinase inhibition activity, and can be applied to treatment of diseases, disorders or symptoms, including B-cell lymphoma, autoimmune diseases, inflammatory diseases and the like, which benefit from inhibitionof Bruton's tyrosine kinase activity, alone or in combination with other drugs.
Quinoline-5,8-dione derivatives for TGase 2 inhibitor, and the pharmaceutical composition comprising the same
-
Paragraph 0263-0266, (2019/10/29)
The present invention relates to a quinolin-5,8-dione derivative compound represented by chemical formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound represented by chemical formula I of the present invention has a TGase 2 inhibitory effect, and the pharmaceutical composition comprising the same can be usefully used for preventing or treating disorders or diseases mediated by TGase 2 or response to TGase 2 inhibition.COPYRIGHT KIPO 2020
Selective Bruton's tyrosine kinase inhibitor and application thereof
-
Paragraph 0194-0196, (2018/06/04)
The invention discloses a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, preparation and application thereof to preparation of medicines for treating diseases, disorders or symptoms obtained from inhibition of Bruton's tyrosine kinase activity. The compound disclosed by the invention has anti-proliferation and inhibition effects on tumor cell lines including A549, MINO, OCI-LY10, TMD-8 and the like, has good anti-tumor activity in tumor models including Mino subcutaneous xenoplastic transplantation and the like and can be applied to medicines for treating solid tumors or leukemia related to human or animal cell proliferation; the compound disclosed by the invention has relatively good pharmacokinetic performance and can be orally taken to treat the solid tumors or the leukemia related to the human or animal cell proliferation or autoimmune diseases; the compound disclosed by the invention has a low hERG channel blocking property.
MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES
-
Page/Page column 40, (2010/04/23)
Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION
-
Page/Page column 28, (2009/12/05)
The present invention relates to processes for the preparation of heteroaryl ethers. In some embodiments, the processes relate to cross coupling reactions between triazol-1-yloxy and triazol-1-yl heterocycles with aryl boronic acids. In a further aspect, this invention also relates to compounds that are useful for the treatment of oncological diseases or disorders, and for the treatment of inflammation.
Heteroaryl ethers by oxidative palladium catalysis of pyridotriazol-1-yloxy pyrimidines with arylboronic acids
Bardhan, Sujata,Wacharasindhu, Sumrit,Wan, Zhao-Kui,Mansour, Tarek S.
supporting information; experimental part, p. 2511 - 2514 (2009/10/18)
The oxidative palladium-catalyzed cross-coupling of pyrimidines containing pyridotriazol-1-yloxy (OPt) as either a urea or an amide functional group with arylboronic acids in the presence of Cs2CO3 in DME containing 0.6-1.0% H2
Hydrogen peroxide mediated formation of heteroaryl ethers from pyridotriazol-1-yloxy heterocycles and arylboronic acids
Bardhan, Sujata,Tabei, Keiko,Wan, Zhao-Kui,Mansour, Tarek S.
supporting information; experimental part, p. 5733 - 5736 (2009/12/06)
Pyridotriazol-1-yloxypyrimidine 3 reacts with arylboronic acids under palladium-free, Cs2CO3, (0.8%) H2O2, and DME conditions to produce heteroaryl ethers 4-16 in good yields comparable to the oxidative palladiu
